Cell X Technologies

Cellply is a deep tech company with the ambition to develop analytical tools enabling fast end effective development of life-saving cancer cell therapies. Our team features a unique combination of expertise in a diverse set of technology going from microfluidics to robotics, AI, biology and immunology. During Advanced Therapies Week 2024 in Miami we officially launched our flagship product, VivaCyte®.

Celligent Diagnostics, is a high-complexity CLIA-certified clinical laboratory, that provides Histology, Cytology and pharma services specializing in cancer diagnostic testing. Celligent has mature working partnerships with several domestic and international research firms. Celligent offers a flexible and complete Cytology testing pallet for the Obstetrics and Gynecology industry. Celligent Diagnostics is committed to delivering innovative pathology services to meet the diagnostic needs of the medical community, and help improve patient care through timely and accurate pathology. Celligent Diagnostics is committed to delivering innovative pathology services to meet the diagnostic needs of the medical community, and help improve patient care through timely and accurate pathology. The Celligent Diagnostics Ancillary Testing Order Form provides our clients and referring locations with an easy-to-use web form users can complete from any device with an internet connection or take the tried and truth method and print, complete, scan and send back. We offer the clinical expertise of over 30 board certified pathologists covering multiple sub-specialties. Our testing menu provides in-house testing of over 200 IHC special stains, HR HPV-ISH testing and industry leading biomarkers such as PD-L1 testing.

We are focussed on developing cell and gene therapies to treat incurable or poorly treated diseases including cancer and heart failure. At Celixir, our values drive all that we do. Specialist – we are dedicated to delivering medical firsts in specific disease areas where innovation is needed. Virtuous – we have a track-record of delivering on our promises and operating with integrity in all of our business interactions. Access-driven – our mission is to change the lives of patients in need and this commitment is underpinned by tireless efforts to ensure global access to our medicines.

At Cellgen, we are developing a universal clinical trial ecosystem that allows life science companies to transform and automate their business processes into the cloud, while also achieving real-time interoperability and analytics of all data, documents, and processes.

Cellics Therapeutics leverages the multifaceted Cellular Nanoparticle (CNP™) technology to develop nano-therapeutics. Cellics’ dynamic nanoplatform, Cellular Nanosponges, harnesses the power of cell membranes to craft specialized nanoparticle-based therapeutics. Cellics is a privately held San Diego-based biopharmaceutical company founded by UC San Diego Professor Liangfang Zhang. We are honest with ourselves and transparent with our actions. We are tireless in applying scientific excellence to seek new solutions for big problems. We are inspired to take action, to be courageous, to break boundaries, for the well-being of patients. Cellics and UCSD have a close collaboration to further develop core platform technologies. Cellics and CARB-X have a strategic partnership of up to $15 Million to develop a novel macrophage nanosponge for treating sepsis.

Our mission is to advance innovative solutions to unresolved chronic diseases and address the growing challenges of the biomedical industry through the promotion of translational research along with the development and commercialization of biotechnology platforms. We develop life-changing therapies and implants for unresolved chronic diseases and tackle the growing challenges of the biomedical industry through visionary life science tools. We aspire to become a world-renowned catalyst of regenerative medicine companies and products that contribute to enabling access to advanced medical treatments with high impact on patients’ health and well-being. Cells for Cells is strongly committed to time-sensitive and cost-efficient clinical and IP validation, a pledge that allowed us to achieve the first-ever clinical proof of principle of an exosome-produced therapy for joint disease. We aim to provide hope to patients in urgent need of satisfactory medical solutions by reducing cost and geographical barriers to accessing advanced therapeutic products. At Cells for Cells, we are devoted to quality. Since 2010, we have been Latin America’s leading company producing cell therapies and innovative tissue engineering solutions, each complying with national and international Good Manufacturing Practices (GMP) regulations related to quality and safety. We focus on continuous improvement thanks to our Quality Management System (QMS) based on ISO 9001:2015, our corporate values, and the experience and professionalism of our teams.